- Details
- E David Crawford interviews Jason Efstathiou about the PARTIQoL trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. The trial, involving 450 patients from 29 centers, focuses on patient-reported outcomes, particularly bowel function at 24 months. Dr. Efstathiou presents the study's design, methodology, and key findings. The results show no significant diff...
|
- Details
- Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no significant differences in tumor control or patient-reported quality of life between the two treatment modalities for low and intermediate-risk prostate cancer patients. He emphasizes the importance of this f...
|
- Details
- Jason Efstathiou discusses the PARTIQoL trial, a randomized phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou discusses the history and potential benefits of proton therapy, as well as the challenges in conducting comparative studies. He describes the trial design, which focuses on patient-reported outcomes, particularly bowel function at 24 months...
|
- Details
- Brian Flynn discusses the emerging field of functional urology. Dr. Flynn defines functional urology as a comprehensive approach to non-cancer, non-stone, adult urological issues, focusing on restoring patients' functionality. He positions it as a bridge between reconstructive and traditional urology, emphasizing the need for expertise in both surgical techniques and physiological understanding. D...
|
- Details
- In this follow-up discussion, Badar Mian and E David Crawford delve deeper into the implications of clinical trials comparing transperineal (TP) and transrectal (TR) prostate biopsies. They address key issues such as antibiotic use, patient comfort, and sampling accuracy. Dr. Mian notes that many European centers still use antibiotics for TP biopsies, contrary to claims of antibiotic avoidance. Th...
|
- Details
- Badar Mian discusses randomized clinical trials comparing transperineal (TP) and transrectal (TR) prostate biopsy approaches. Despite previous beliefs favoring TP biopsies for lower infection rates and better cancer detection, three major trials (ProBE-PC, PREVENT, and PERFECT) show no significant differences in sepsis rates or cancer detection between the two methods. The studies reveal similar m...
|
- Details
- David Albala discusses the emerging field of telesurgery. Dr. Albala highlights the evolution from traditional surgical training to robotic surgery, and now to telesurgery, where surgeons can operate remotely. He mentions key milestones, including the first transatlantic telesurgery in 1998, and recent advancements in China and Japan. Dr. Albala emphasizes the potential of telesurgery to address h...
|
- Details
- David Staskin discusses the COURAGE trial, a phase three study evaluating the efficacy of Vibegron, a beta-3 adrenergic receptor agonist, in men with BPH and persistent OAB symptoms despite alpha-blocker treatment. The study demonstrates significant improvements in various urinary symptoms, including micturitions, urgency episodes, and nocturia. Dr. Staskin highlights the drug's favorable safety p...
|
- Details
- David Crawford discusses advancements in advanced urothelial cancer treatment with Daniel Petrylak. Dr. Petrylak highlights the success of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, combined with pembrolizumab. This combination demonstrates significant improvements in response rates and survival compared to standard chemotherapy, with a 30% complete response rate and d...
|
- Details
- David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases....
|
